Title |
The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40
|
---|---|
Published in |
BMC Cancer, December 2014
|
DOI | 10.1186/1471-2407-14-969 |
Pubmed ID | |
Authors |
Andrea Khong, Amanda L Cleaver, Muhammad Fahmi Alatas, Ben C Wylie, Theresa Connor, Scott A Fisher, Steve Broomfield, Willem J Lesterhuis, Andrew J Currie, Richard A Lake, Bruce W Robinson |
Abstract |
Tumor debulking surgery followed by adjuvant chemotherapy or radiotherapy is a standard treatment for many solid malignancies. Although this approach can be effective, it often has limited success against recurrent or metastatic cancers and new multimodality approaches are needed. Adjuvant immunotherapy is another potentially effective approach. We therefore tested the efficacy of the TLR7 agonist imiquimod (IMQ) combined with agonistic anti-CD40 as adjuvant in an incomplete debulking surgical model of solid cancer. We tested the efficacy of adjuvant imiquimod (IMQ) combined with agonistic anti-CD40 in an incomplete debulking model of malignant mesothelioma. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 47 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 10 | 21% |
Researcher | 7 | 15% |
Student > Master | 4 | 9% |
Student > Bachelor | 4 | 9% |
Unspecified | 3 | 6% |
Other | 9 | 19% |
Unknown | 10 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 9 | 19% |
Immunology and Microbiology | 7 | 15% |
Agricultural and Biological Sciences | 6 | 13% |
Unspecified | 3 | 6% |
Engineering | 2 | 4% |
Other | 7 | 15% |
Unknown | 13 | 28% |